{
    "clinical_study": {
        "@rank": "18378", 
        "acronym": "GC-A-003", 
        "arm_group": {
            "arm_group_label": "albumin-bounded paclitaxel plus S-1", 
            "arm_group_type": "Experimental", 
            "description": "arm 1:albumin-bounded paclitaxel 200mg iv d1  and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are\n      effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma."
        }, 
        "brief_title": "First Line Chemotherapy for Advanced Cancer", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This phase II study was designed to evaluate the efficacy and safety of albumin-bounded\n      paclitaxel combined with S-1 as first-line chemotherapy for inoperable and /or metastatic\n      gastric or gastroesophageal junction cancer.Primary endpoint was overall response rate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inoperable locally advanced, recurrent, and/or metastatic adenocarcinoma of the\n             stomach or gastro-esophageal junction\n\n          -  Adult patients >=18 years of age\n\n          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;\n\n          -  At least have one measurable disease(according to RECIST)\n\n          -  Adequate bone marrow,renal and liver function\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy for advanced/metastatic disease\n\n          -  Lack of physical integrity of the upper gastrointestinal tract, or malabsorption\n             syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980810", 
            "org_study_id": "CH-GI-037-nab"
        }, 
        "intervention": [
            {
                "arm_group_label": "albumin-bounded paclitaxel plus S-1", 
                "description": "200mg iv d1,  repeat every 2 weeks,until disease progression,or up to 9 cycles", 
                "intervention_name": "albumin-bounded paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Abraxane", 
                    "Paclitaxel Albumin-stabilized Nanoparticle Formulation"
                ]
            }, 
            {
                "arm_group_label": "albumin-bounded paclitaxel plus S-1", 
                "description": "40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug", 
                "other_name": "TS-1"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "song-yan@hotmail.com", 
                "last_name": "Yan Song, MD", 
                "phone": "86-10-87788145"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Department of Medical Oncology,Cancer Hostpital and Institute,CAMS"
            }, 
            "investigator": {
                "last_name": "Lin Yang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma", 
        "overall_contact": {
            "email": "song-yan@hotmail.com", 
            "last_name": "Yan Song, MD", 
            "phone": "010-87788145"
        }, 
        "overall_official": {
            "affiliation": "Department of medical oncology,Cancer hospital and institute,CAMS", 
            "last_name": "Lin Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "response rate", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980810"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Lin Yang", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "number of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}